By detailed phenotyping of major NK receptors in NK cells isolated from treated CML patients, we confirmed previous findings and also observed that global NK activities were reduced at the onset of CML, along with reduction of major NK activating receptors like NKG2D, NKP30, and DNAM-1, and with increase of inhibitory receptor NKG2A levels (Figure 1A). This evidence concerns the gene KLRC1 and chronic myelogenous leukemia, BCR-ABL1 positive.